Loading financial data...

Calidi Biotherapeutics, Inc. (CLDWW) Financial Statements | Global Financial Data

Calidi Biotherapeutics, Inc.

CLDWWSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1855485

Concept	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	$45.0K	—	—
Research and Development Expense	$13.0M	$7.3M	—	—
Selling, General and Administrative Expense	$16.0M	$15.9M	—	—
Operating Expenses	$29.0M	$23.2M	$1.8M	$1.8M
Operating Income (Loss)	-$29.0M	-$23.1M	-$1.8M	-$1.8M
Nonoperating Income (Expense)	-$208.0K	-$2.3M	$5.2M	$5.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$29.2M	-$25.4M	$3.4M	—
Income Tax Expense (Benefit)	$16.0K	$11.0K	$0.00	—
Net Income (Loss) Attributable to Parent	-$29.2M

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$10.0M	$2.6M	$231.8M	$231.8M
Assets, Current	$4.3M	$786.0K	$1.5M	$1.5M
Cash and Cash Equivalents, at Carrying Value	$9.6M	—	—	$1.1M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$0.00	—
Liabilities	$18.3M	$43.4M	$16.5M	$16.5M
Liabilities, Current	$10.2M	$43.0M	$411.0K	$411.0K
Long-term Debt	$2.1M	$2.1M	—	—
Accounts Payable, Current	—	—	$63.8K	$63.8K
Stockholders' Equity Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$27.0M	-$13.2M	-$1.1M	-$1.1M
Net Cash Provided by (Used in) Investing Activities	-$478.0K	-$494.0K	-$230.0M	-$230.0M
Net Cash Provided by (Used in) Financing Activities	$29.0M	$12.1M	$232.1M	$232.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)